Skip to main content

EVA - patient ventilation beyond limits

Objective

EVA - Expiratory Ventilation Assistance – , or expiration by suction, is an innovative method to mechanically ventilate patients and is a key step in ventilation towards less-invasive, tailored and improved patient care as it enables:
1. full ventilation through a thin catheter instead of a thick tube
2. low and – if needed – negative pressures in the lungs promoting blood circulation
3. controlling the expiration, reducing sheer stress, which may prevent lung injury and improve patient outcome.

The EVA technology has already been on the market for some years in its most basic form: the manual, disposable emergency ventilator Ventrain®. Since market launch in 2011, Ventrain® is now being sold by 16 distributors in over 20 countries.
Ventinova’s flagship is the “EVA device”: a fully automated ventilator based on EVA technology meeting the emerging needs of less invasive, tailored and improved patient care. First is focused on the large markets of elective surgical procedures and emergency care (€ 400 M, globally) and in 2nd generation on ICU-ventilation (€ 500 M, globally), before becoming ‘standard care’ (€ 4.6 billion, globally). The device, currently at TRL6, is still in development and CE marking is expected in Q3 2016. Next to marketing activities, such as organizing workshops and training sessions, and careful selection and support of distributors, penetration of the conservative medical market should be ensured by demonstration of better and tailored patient care using EVA ventilation in pre-clinical studies and controlled clinical trials. These are to be designed and executed in close collaboration with Key Opinion Leaders of established and world leading academic medical centers.

The described technology and products are protected by 5 patent families and design and brand registrations. The products are manufactured in The Netherlands and a dedicated catheter in Ireland. After CE marking, large non-EU markets are to be entered (e.g. USA, China, Russia).

Coordinator

VENTINOVA MEDICAL BV
Net EU contribution
€ 793 261,87
Address
Meerenakkerplein 7
5652 BJ Eindhoven
Netherlands

See on map

Region
Noord-Brabant Zuidoost-Noord-Brabant
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 793 261,87

Participants (4)

UNIVERSITAETSKLINIKUM FREIBURG
Germany
Net EU contribution
€ 621 250,00
Address
Hugstetter Strasse 49
79106 Freiburg

See on map

Region
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 621 250,00
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Participation ended

France
Net EU contribution
€ 21 487,50
Address
3 Avenue Victoria
75000 Paris
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 21 487,50
UNITRON INNOTECH BV
Netherlands
Net EU contribution
€ 390 999,88
Address
Asveldweg 2
7556 BP Hengelo

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Oost-Nederland Overijssel Twente
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 390 999,88
REGION HOVEDSTADEN
Denmark
Net EU contribution
€ 63 000,75
Address
Kongens Vaenge 2
3400 Hillerod

See on map

Region
Danmark Hovedstaden Nordsjælland
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 63 000,75